These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 18852722)

  • 41. Cytoreductive nephrectomy in the era of targeted therapies: a review.
    Pindoria N; Raison N; Blecher G; Catterwell R; Dasgupta P
    BJU Int; 2017 Sep; 120(3):320-328. PubMed ID: 28371084
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of cytoreductive nephrectomy in the targeted therapy era: A systematic review and meta-analysis.
    García-Perdomo HA; Zapata-Copete JA; Castillo-Cobaleda DF
    Investig Clin Urol; 2018 Jan; 59(1):2-9. PubMed ID: 29333508
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Salvage paclitaxel chemotherapy for metastatic collecting duct carcinoma of the kidney.
    Bagrodia A; Gold R; Handorf C; Liman A; Derweesh IH
    Can J Urol; 2008 Dec; 15(6):4425-7. PubMed ID: 19046497
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Refining the use of cytoreductive nephrectomy in metastatic renal cell carcinoma.
    La Rochelle J; Wood C; Bex A
    Semin Oncol; 2013 Aug; 40(4):429-35. PubMed ID: 23972706
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytoreductive nephrectomy: A medical oncologist's perspective.
    Dizman N; Maia MC; Pal SK
    Urol Oncol; 2017 May; 35(5):180-182. PubMed ID: 29037531
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Conservative vs radical surgery for renal cell carcinoma.
    Van Poppel H
    BJU Int; 2004 Oct; 94(6):766-8. PubMed ID: 15476505
    [No Abstract]   [Full Text] [Related]  

  • 47. Open radical nephrectomy versus open partial nephrectomy: is it still an issue?
    Ficarra V
    Eur Urol; 2007 Mar; 51(3):593-5. PubMed ID: 17141946
    [No Abstract]   [Full Text] [Related]  

  • 48. The case for partial nephrectomy.
    Dias M; Coombes G
    Ann R Coll Surg Engl; 2008 May; 90(4):280-1. PubMed ID: 18521977
    [No Abstract]   [Full Text] [Related]  

  • 49. Why not partial nephrectomy?
    Navai N; Ramos P; Zhao LC; Meeks JJ; Nadler RB; Smith ND
    Urology; 2008 Aug; 72(2):243-6. PubMed ID: 18584853
    [No Abstract]   [Full Text] [Related]  

  • 50. Prognostic implications of polymorphisms and interleukin-2 therapy for renal cell carcinoma.
    Gardner TA; Logan T
    J Urol; 2009 Aug; 182(2):425-6. PubMed ID: 19524946
    [No Abstract]   [Full Text] [Related]  

  • 51. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
    Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
    Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current treatment of renal cell carcinoma.
    De Mulder PH; van Herpen CM; Mulders PA
    Ann Oncol; 2004; 15 Suppl 4():iv319-28. PubMed ID: 15477330
    [No Abstract]   [Full Text] [Related]  

  • 53. Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature.
    Bandini M; Smith A; Marchioni M; Pompe RS; Martel TF; Cindolo L; Montorsi F; Shariat SF; Briganti A; Kapoor A; Capitanio U; Karakiewicz PI
    Clin Genitourin Cancer; 2018 Jun; 16(3):176-183. PubMed ID: 29449091
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lymph node dissection in the management of renal cell carcinoma.
    Leibovich BC; Blute ML
    Urol Clin North Am; 2008 Nov; 35(4):673-8; viii. PubMed ID: 18992620
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Re: Henderson A et al: Hand-assisted laparoscopic nephrectomy for renal cell cancer with renal vein tumor thrombus (Urology 2008;72:268-272).
    Chung SD; Lin TY; Lu CW
    Urology; 2009 Feb; 73(2):448-9; author reply 449. PubMed ID: 19185764
    [No Abstract]   [Full Text] [Related]  

  • 56. Elective Cytoreductive Nephrectomy After Checkpoint Inhibitor Immunotherapy in Patients With Initially Unresectable Metastatic Clear Cell Renal Cell Carcinoma.
    Reimers MA; Figenshau RS; Kim EH; Tucker J; Kasten N; Khan AS; Hanneken JM; Smith ZL; Hsieh JJ
    Clin Genitourin Cancer; 2020 Oct; 18(5):361-366. PubMed ID: 32417157
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumour nephrectomy with vena cava thrombus.
    Ciancio G; Soloway M
    BJU Int; 2006 Jan; 97(1):198-9. PubMed ID: 16336360
    [No Abstract]   [Full Text] [Related]  

  • 58. Re: Berger AD, et al.: Transperitoneal laparoscopic radical nephrectomy for large (>7 cm) renal masses (Urology 2008;71:421-424).
    Chung SD; Chen KH; Chen HA
    Urology; 2009 Feb; 73(2):447; author reply 447-8. PubMed ID: 19185763
    [No Abstract]   [Full Text] [Related]  

  • 59. Editorial comment on: preservation of renal function following partial or radical nephrectomy using 24-hour creatinine clearance.
    Kirkali Z
    Eur Urol; 2008 Jul; 54(1):151-2. PubMed ID: 18407403
    [No Abstract]   [Full Text] [Related]  

  • 60. Editorial comment on: preservation of renal function following partial or radical nephrectomy using 24-hour creatinine clearance.
    Russo P
    Eur Urol; 2008 Jul; 54(1):149-50. PubMed ID: 18407405
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.